Sysmex (OTCMKTS:SSMXY) Updates FY 2024 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.590-0.590 for the period. The company issued revenue guidance of $3.4 billion-$3.4 billion.

Sysmex Trading Up 4.7 %

Shares of SSMXY stock traded up $0.88 during mid-day trading on Friday, hitting $19.71. 39,701 shares of the company’s stock were exchanged, compared to its average volume of 52,427. The stock has a market cap of $12.40 billion, a price-to-earnings ratio of 37.16 and a beta of 0.84. The stock has a 50-day simple moving average of $19.22 and a two-hundred day simple moving average of $17.60. Sysmex has a fifty-two week low of $14.38 and a fifty-two week high of $29.78. The company has a quick ratio of 2.40, a current ratio of 3.23 and a debt-to-equity ratio of 0.11.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.11 earnings per share for the quarter. The company had revenue of $718.13 million during the quarter. Equities analysts expect that Sysmex will post 0.57 EPS for the current fiscal year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.